Chapter 39 — Pharmacological Management of Coagulation Disorders — Module 5 — Antiplatelet Therapy: From Aspirin to Novel Agents
1. A 58-year-old man with a history of myocardial infarction is maintained on aspirin 81 mg daily for secondary prevention. He asks his cardiologist why he must take the aspirin every day rather than every few days, since he understands the drug "stays in the blood" for a long time. The cardiologist explains that the relevant pharmacodynamic feature governing the dosing interval is not plasma half-life but rather the duration of effect on the target cell. Which of the following most accurately describes the mechanism underlying the sustained antiplatelet effect of a single aspirin dose?
A) Aspirin competitively inhibits the P2Y12 ADP receptor on platelets, requiring new receptor synthesis for platelet function to recover.
B) Aspirin irreversibly acetylates cyclooxygenase-1 (COX-1) at serine-529, permanently inactivating the enzyme in that platelet for its lifespan.
C) Aspirin inhibits thromboxane synthase in platelets, reducing TXA2 production until the enzyme is resynthesized over several days.
D) Aspirin blocks integrin alphaIIb beta3 (GP IIb/IIIa) activation through covalent modification, preventing fibrinogen crosslinking for 7 to 10 days.
E) Aspirin acetylates and inhibits phospholipase A2, blocking arachidonic acid release from membrane phospholipids for the platelet lifespan.
ANSWER: B
Rationale:
Aspirin produces its antiplatelet effect by irreversibly acetylating COX-1 (cyclooxygenase-1) at serine-529 within the enzyme's active channel. Because platelets are anucleate and cannot synthesize new COX-1 protein, a single acetylation event permanently abolishes TXA2 (thromboxane A2) synthesis in that platelet for its entire lifespan of approximately 7 to 10 days. This explains both the prolonged duration of antiplatelet effect relative to the short plasma half-life of aspirin (15 to 20 minutes) and the rationale for once-daily dosing: daily dosing ensures that newly released platelets (approximately 10 to 15% of the circulating pool is replaced each day) are continuously acetylated before they can contribute to pathological thrombus formation.
Option A: Option A is incorrect: clopidogrel and related thienopyridines target P2Y12, not aspirin.
Option C: Option C is incorrect: aspirin's target is COX-1 (the prostaglandin endoperoxide synthase), not thromboxane synthase, which is a downstream enzyme in the TXA2 synthesis pathway; selective thromboxane synthase inhibitors exist but aspirin is not among them.
Option D: Option D is incorrect: aspirin does not affect GP IIb/IIIa; that receptor is the target of abciximab, eptifibatide, and tirofiban.
Option E: Option E is incorrect: phospholipase A2 is not acetylated by aspirin; PLA2 remains functional and continues to release arachidonic acid, but with COX-1 inactivated, the released arachidonic acid cannot be converted to the prostaglandin endoperoxides that feed TXA2 synthesis.
2. A pharmacology lecturer is explaining why blocking the P2Y12 receptor produces more potent and sustained antiplatelet effects than blocking the P2Y1 receptor, even though both are activated by adenosine diphosphate (ADP). She states that the key difference lies in the G-protein coupling and downstream signaling of P2Y12. Which of the following correctly describes the intracellular mechanism by which P2Y12 activation sustains platelet aggregation?
A) P2Y12 is coupled to Gs, stimulating adenylyl cyclase and raising cyclic AMP (cAMP), which activates protein kinase A to promote platelet shape change.
B) P2Y12 is coupled to Gq, triggering phospholipase C-beta activation with IP3-mediated calcium release, producing a sustained rise in intracellular calcium.
C) P2Y12 is coupled to Gi, inhibiting adenylyl cyclase and reducing cyclic AMP (cAMP), which sustains platelet activation by preventing PKA-mediated inhibition of aggregation.
D) P2Y12 is coupled to G12/13, activating Rho kinase and driving cytoskeletal reorganization required for the platelet shape change that precedes aggregation.
E) P2Y12 is coupled to Gq and directly activates phospholipase A2, releasing arachidonic acid for TXA2 synthesis independent of the COX-1 pathway.
ANSWER: C
Rationale:
P2Y12 is a Gi-coupled purinergic receptor. When activated by ADP, its Gi subunit dissociates and inhibits adenylyl cyclase, reducing intracellular cyclic AMP (cAMP) levels. Because elevated cAMP activates protein kinase A (PKA), which phosphorylates and inhibits multiple components of the platelet activation machinery (including vasodilator-stimulated phosphoprotein, VASP), the reduction in cAMP removes this inhibitory brake and sustains platelet activation and aggregation. This sustained signaling through P2Y12 is the reason that blocking P2Y12 alone is sufficient to substantially impair stable platelet aggregation driven by ADP even when P2Y1 remains functional.
Option A: Option A is incorrect: Gs coupling would stimulate adenylyl cyclase and raise cAMP, which would actually inhibit platelet activation — this is the mechanism by which prostacyclin (PGI2) and agents like dipyridamole exert their antiplatelet effects.
Option B: Option B is incorrect: Gq coupling with IP3-mediated calcium release describes P2Y1, not P2Y12; P2Y1 produces a transient calcium signal but does not sustain aggregation independently.
Option D: Option D is incorrect: G12/13 coupling with Rho kinase activation describes the signaling of thrombin via PAR-1 and PAR-4 receptors, not the primary mechanism of P2Y12.
Option E: Option E is incorrect: P2Y12 does not couple to Gq and does not directly activate phospholipase A2; furthermore, the COX-1/TXA2 pathway is downstream of PLA2 and is aspirin's target, not a P2Y12 effector.
3. A 64-year-old woman with acute coronary syndrome undergoes coronary stenting and is started on clopidogrel 75 mg daily. Her cardiologist notes she is a CYP2C19 poor metabolizer based on prior pharmacogenomic testing. The resident asks why this genotype specifically affects clopidogrel but not ticagrelor response. The attending explains that the key difference lies in the pharmacokinetic classification of these agents. Which of the following best characterizes clopidogrel's mechanism of action and the step at which poor metabolizer status exerts its effect?
A) Clopidogrel is a direct-acting P2Y12 antagonist that binds the ADP binding site; CYP2C19 poor metabolizer status reduces hepatic first-pass elimination, increasing drug exposure and paradoxically worsening bleeding risk.
B) Clopidogrel irreversibly blocks P2Y1 receptors after bioactivation by CYP2C19; poor metabolizer status impairs this conversion, leaving the Gq-mediated transient calcium signal intact.
C) Clopidogrel is converted by CYP2C19 to an active thiol metabolite that irreversibly acetylates P2Y12; poor metabolizer status reduces the thiol yield, limiting the degree of platelet inhibition.
D) Clopidogrel requires two sequential CYP steps for bioactivation, with CYP2C19 responsible for both; poor metabolizer status impairs the first oxidation step only, allowing partial compensatory activation by CYP3A4.
E) Clopidogrel is a prodrug requiring two sequential hepatic oxidation steps, the second of which is catalyzed primarily by CYP2C19 to generate an active thiol metabolite that irreversibly binds and inactivates P2Y12; poor metabolizer status reduces active metabolite formation and platelet inhibition.
ANSWER: E
Rationale:
Clopidogrel is a thienopyridine prodrug that undergoes two sequential hepatic oxidation steps to generate its pharmacologically active thiol metabolite. The first step is primarily catalyzed by CYP1A2 and CYP2C19 and converts clopidogrel to an intermediate (2-oxo-clopidogrel); the second step is catalyzed predominantly by CYP2C19 (along with CYP3A4, CYP2B6, and CYP2C9) and generates the active thiol. This active thiol then forms a disulfide bond with cysteine residues in the P2Y12 receptor, producing irreversible blockade. In CYP2C19 poor metabolizers, reduced enzymatic activity at the second (and to a lesser extent the first) oxidation step produces substantially less active thiol, resulting in inadequate platelet inhibition and higher rates of MACE including stent thrombosis.
Option A: Option A is incorrect: clopidogrel is a prodrug, not a direct-acting agent, and CYP2C19 poor metabolizer status reduces, not increases, drug effect.
Option B: Option B is incorrect: clopidogrel targets P2Y12, not P2Y1, and the mechanism is covalent binding of a thiol metabolite, not acetylation.
Option C: Option C is incorrect: the mechanism of P2Y12 inactivation by the thiol metabolite is covalent disulfide bond formation, not acetylation; acetylation is specific to aspirin's mechanism at COX-1.
Option D: Option D is incorrect: while two CYP steps are involved, CYP2C19 is not responsible for both — the first step involves CYP1A2 and CYP2C19 in combination, and while CYP3A4 does participate in the second step, it cannot fully compensate for CYP2C19 deficiency in poor metabolizers, as evidenced by the clinical outcomes data from TRITON-TIMI 38 subgroup analyses.
4. During a cardiology teaching conference, a fellow is asked to explain why glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors produce the most complete platelet inhibition of any available antiplatelet class, yet also carry the highest bleeding risk. The fellow correctly explains that the answer relates to the position of GP IIb/IIIa in the platelet activation sequence. Which of the following best describes the role of GP IIb/IIIa in platelet aggregation and the basis for its designation as the "final common pathway"?
A) GP IIb/IIIa (integrin alphaIIb beta3) is expressed in high-affinity conformation on resting platelets but undergoes inside-out signaling upon platelet activation to bind fibrinogen, crosslinking adjacent platelets regardless of which upstream activation signal (TXA2, ADP, or thrombin) initiated the response.
B) GP IIb/IIIa functions as an ADP-gated ion channel at the platelet surface; when activated by any stimulus, it allows calcium influx that then triggers fibrinogen receptor exposure on adjacent platelets.
C) GP IIb/IIIa is a thrombin receptor expressed on platelet-rich thrombi; its inhibition prevents thrombin amplification of the platelet plug but does not affect primary platelet adhesion to collagen.
D) GP IIb/IIIa is constitutively active and mediates platelet rolling along the endothelium under resting conditions; its pharmacological blockade prevents inappropriate platelet-endothelium interactions in atherosclerotic vessels.
E) GP IIb/IIIa inhibition is most effective when initiated upstream of platelet activation, because the receptor requires de novo synthesis after platelet activation to achieve high-affinity fibrinogen binding.
ANSWER: A
Rationale:
GP IIb/IIIa (integrin alphaIIb beta3) is the final common pathway for platelet aggregation because it is the convergent effector for all platelet activation signals. In resting platelets, GP IIb/IIIa is maintained in a low-affinity conformation with minimal affinity for soluble fibrinogen. Upon activation by any stimulus — whether TXA2 via TP receptors, ADP via P2Y12, thrombin via PAR-1/PAR-4, or collagen via GP VI — intracellular signals activate talin and kindlin-3, which bind the cytoplasmic tail of the beta3 subunit and drive conformational change to a high-affinity state (inside-out signaling). The high-affinity receptor then binds fibrinogen (or vWF under high shear), and fibrinogen crosslinks GP IIb/IIIa on adjacent platelets to form the platelet aggregate. Each platelet expresses approximately 80,000 copies of GP IIb/IIIa. Because blockade at this final step interrupts aggregation regardless of which upstream pathway is active, GP IIb/IIIa inhibitors produce the most complete platelet inhibition — and correspondingly the highest bleeding risk of any antiplatelet class.
Option B: Option B is incorrect: GP IIb/IIIa is an integrin (cell adhesion receptor), not an ion channel; it does not gate calcium flux.
Option C: Option C is incorrect: GP IIb/IIIa is not a thrombin receptor; thrombin acts through PAR-1 and PAR-4 on the platelet surface; GP IIb/IIIa inhibition blocks aggregation, not thrombin-receptor signaling.
Option D: Option D is incorrect: GP IIb/IIIa is not constitutively active on resting platelets; it requires inside-out activation to achieve high affinity; the GP Ib-IX-V complex mediates platelet rolling and tethering to vWF.
Option E: Option E is incorrect: platelets are anucleate and cannot synthesize new GP IIb/IIIa; the receptor is present at fixed numbers on each platelet and does not require de novo synthesis.
5. A 71-year-old man presents with a non-ST-elevation myocardial infarction (NSTEMI) and undergoes percutaneous coronary intervention (PCI) with drug-eluting stent placement. His past medical history includes a transient ischemic attack (TIA) two years prior, type 2 diabetes mellitus, and hypertension. His weight is 78 kg. The interventional cardiologist is selecting a P2Y12 inhibitor for post-PCI dual antiplatelet therapy. Prasugrel is considered. Which of the following represents the strongest contraindication to prasugrel use in this patient?
A) His age of 71 years, which places him in a subgroup where prasugrel dosing should be reduced to 5 mg daily to avoid excess bleeding.
B) His diagnosis of type 2 diabetes mellitus, in which prasugrel's CYP-dependent bioactivation is impaired by insulin resistance-related CYP2C19 downregulation.
C) His weight of 78 kg, which exceeds the threshold of 60 kg below which prasugrel is associated with net harm and dose reduction to 5 mg daily is indicated.
D) His history of a prior transient ischemic attack (TIA), which is an absolute contraindication to prasugrel use based on net harm demonstrated in the TRITON-TIMI 38 trial.
E) His NSTEMI presentation, for which prasugrel has no approved indication and only clopidogrel is FDA-approved for ACS without ST-elevation.
ANSWER: D
Rationale:
A history of prior stroke or transient ischemic attack (TIA) is an absolute contraindication to prasugrel use. In the TRITON-TIMI 38 trial (n = 13,608), the subgroup of patients with prior stroke or TIA who received prasugrel had a net clinical harm: the increase in intracranial hemorrhage substantially outweighed any ischemic benefit, yielding a net harm. This finding resulted in a boxed warning and formal contraindication in the prasugrel prescribing information. For this patient, despite a favorable weight and an otherwise appropriate ACS/PCI indication for prasugrel, the prior TIA is an absolute contraindication and mandates use of either clopidogrel or ticagrelor instead.
Option A: Option A is incorrect: while age 75 or older is a relative contraindication to prasugrel (no net benefit in that subgroup), age 71 does not independently trigger the contraindication; furthermore, dose reduction to 5 mg/day is indicated in patients weighing less than 60 kg, not in elderly patients specifically.
Option B: Option B is incorrect: CYP2C19 variation affects clopidogrel, not prasugrel; prasugrel's bioactivation requires only a single CYP step and is substantially less dependent on CYP2C19, and diabetes mellitus does not impair prasugrel bioactivation.
Option C: Option C is incorrect: this patient weighs 78 kg, which is above the 60 kg threshold; dose reduction to 5 mg/day is considered in patients weighing less than 60 kg, not this patient.
Option E: Option E is incorrect: prasugrel is FDA-approved for reducing thrombotic cardiovascular events in patients with ACS (including NSTEMI and STEMI) managed with PCI.
6. A clinical pharmacist is counseling a cardiology fellow on the pharmacological differences between clopidogrel and ticagrelor. The fellow asks why ticagrelor can be given to CYP2C19 poor metabolizers without concern for reduced efficacy, yet ticagrelor still produces more potent and consistent platelet inhibition than clopidogrel even in normal metabolizers. The pharmacist explains that the distinction is rooted in ticagrelor's receptor binding mechanism. Which of the following most accurately describes ticagrelor's mechanism of P2Y12 inhibition?
A) Ticagrelor is a prodrug converted by CYP3A4 to an active thiol that binds covalently to a cysteine residue in the P2Y12 receptor extracellular domain, producing irreversible blockade independent of CYP2C19.
B) Ticagrelor is a direct-acting cyclopentyl-triazolo-pyrimidine that binds P2Y12 at an allosteric site distinct from the ADP binding site, producing reversible, non-competitive inhibition without requiring hepatic bioactivation.
C) Ticagrelor irreversibly occupies the ADP (adenosine diphosphate) binding site of P2Y12 by forming a disulfide bridge with the receptor's transmembrane cysteine residues, with the parent compound being active without any metabolic conversion.
D) Ticagrelor is a direct-acting agent that competitively and reversibly blocks the ADP binding site of P2Y12, with inhibition that is surmountable at sufficiently high local ADP concentrations during high-shear arterial thrombosis.
E) Ticagrelor inhibits both P2Y12 and P2Y1 ADP receptors simultaneously, accounting for its more complete platelet inhibition compared to thienopyridines, which block only P2Y12.
ANSWER: B
Rationale:
Ticagrelor is a cyclopentyl-triazolo-pyrimidine (CPTP) compound that binds P2Y12 directly as the parent drug — no hepatic bioactivation to an active thiol is required. Its binding site is an allosteric site distinct from the ADP binding site, making the inhibition non-competitive: ticagrelor's effect is not surmountable by increasing ADP concentration. The binding is reversible, with platelet function recovering as plasma ticagrelor (and its active metabolite AR-C124910XX) concentrations decline, typically with approximately 50% recovery within 24 to 48 hours of the last dose. Because CYP2C19 is not required for ticagrelor's pharmacological activity (no thiol intermediate is generated), CYP2C19 genotype does not affect its antiplatelet efficacy.
Option A: Option A is incorrect: ticagrelor does not produce a thiol metabolite and does not act via covalent disulfide bond formation; disulfide bond formation is the mechanism of the thienopyridine active metabolites (clopidogrel and prasugrel).
Option C: Option C is incorrect: ticagrelor does not form a disulfide bridge and its inhibition is reversible, not irreversible; irreversible covalent disulfide binding is specific to the thienopyridine class.
Option D: Option D is incorrect: ticagrelor binds at an allosteric, not orthosteric (ADP binding), site; thus the inhibition is non-competitive and is not surmountable by high ADP concentrations — this distinction is clinically important in high-shear, high-ADP states.
Option E: Option E is incorrect: ticagrelor does not inhibit P2Y1; its specificity is for P2Y12 at the allosteric binding site.
7. A 55-year-old man with an NSTEMI (non-ST-elevation myocardial infarction) arrives in the cardiac catheterization laboratory for urgent PCI (percutaneous coronary intervention). He was unable to take oral medications due to persistent vomiting in the emergency department and has not received any P2Y12 inhibitor pre-loading. The interventional team decides to use cangrelor as the procedural antiplatelet agent. Which of the following best describes the pharmacokinetic properties that make cangrelor appropriate for this clinical situation?
A) Cangrelor is a prodrug that is rapidly activated by plasma esterases within minutes of intravenous infusion, achieving effective P2Y12 blockade within 15 minutes with a platelet function offset of 4 to 6 hours after infusion cessation.
B) Cangrelor is an oral P2Y12 antagonist with a loading dose of 180 mg that achieves peak platelet inhibition within 30 minutes; it is appropriate when IV access is unreliable but the patient can swallow.
C) Cangrelor is an intravenous ATP analogue that directly and reversibly inhibits P2Y12, achieving near-maximal platelet inhibition within minutes of starting the infusion and restoring platelet function within 60 to 90 minutes of stopping it.
D) Cangrelor is an intravenous thienopyridine prodrug that is bioactivated to an active thiol within the hepatic circulation; its offset is rapid (within 2 hours) because the covalent bond with P2Y12 is weaker than that formed by clopidogrel.
E) Cangrelor is an intravenous direct thrombin inhibitor that also inhibits platelet aggregation by blocking PAR-1; its short half-life makes it ideal for bridging anticoagulation and antiplatelet therapy simultaneously.
ANSWER: C
Rationale:
Cangrelor is an intravenous adenosine triphosphate (ATP) analogue that directly and reversibly inhibits the P2Y12 ADP receptor. Because it is a direct-acting agent (not a prodrug), it achieves near-maximum platelet inhibition within minutes of starting the infusion. Its plasma half-life is approximately 3 to 5 minutes, and after the infusion is stopped, platelet function recovers to baseline within 60 to 90 minutes as drug concentration falls and the reversible binding dissipates. These combined properties — immediate onset and rapid, predictable offset — make it ideal for procedural settings (PCI) where the patient cannot take oral medications, where pre-loading has not occurred, and where it may be necessary to cease antiplatelet coverage rapidly if a surgical complication arises.
Option A: Option A is incorrect: cangrelor is not a prodrug and does not require activation by plasma esterases; it is a direct-acting IV compound with onset in minutes; platelet function offset of 4 to 6 hours would describe eptifibatide or tirofiban, not cangrelor.
Option B: Option B is incorrect: cangrelor is an intravenous agent, not oral; the loading dose described (180 mg, 30-minute onset) matches ticagrelor.
Option D: Option D is incorrect: cangrelor is not a thienopyridine and does not form a covalent bond with P2Y12; covalent (irreversible) P2Y12 binding is the mechanism of clopidogrel's and prasugrel's active metabolites.
Option E: Option E is incorrect: cangrelor is a P2Y12 receptor antagonist, not a thrombin inhibitor or PAR-1 antagonist; vorapaxar is the only approved PAR-1 antagonist for antiplatelet use; bivalirudin and argatroban are direct thrombin inhibitors.
8. A cardiologist is explaining to an interventional fellow why abciximab behaves differently from eptifibatide and tirofiban in terms of offset kinetics, even though all three agents inhibit GP IIb/IIIa (glycoprotein IIb/IIIa). The fellow is surprised that platelet function recovers faster after eptifibatide infusion than after abciximab infusion despite eptifibatide having a longer plasma half-life. Which of the following best explains abciximab's structural characteristics and the reason its platelet-level effect persists well beyond plasma clearance?
A) Abciximab is a small-molecule RGD (arginine-glycine-aspartic acid) mimetic with high receptor selectivity for alphaIIb beta3; it undergoes rapid hepatic metabolism but its metabolites accumulate in platelet membranes, maintaining GP IIb/IIIa blockade.
B) Abciximab is a cyclic heptapeptide that competitively inhibits GP IIb/IIIa; its prolonged platelet-level effect reflects extensive enterohepatic recirculation that sustains plasma concentrations despite rapid renal elimination.
C) Abciximab is a non-peptide tyrosine derivative that forms a covalent thioester bond with GP IIb/IIIa's beta3 subunit; platelet function recovery requires new GP IIb/IIIa synthesis, which takes 7 to 10 days in platelets derived from megakaryocytes.
D) Abciximab competitively and reversibly inhibits GP IIb/IIIa but is sequestered in platelet cytoplasm after receptor binding and released gradually over 14 to 21 days, producing prolonged drug exposure at the platelet level.
E) Abciximab is a chimeric human-murine monoclonal antibody Fab fragment that binds GP IIb/IIIa with very high affinity and functionally irreversible kinetics; it redistributes from inhibited to newly released platelets over 14 to 21 days, diluting the inhibitory effect as new uninhibited platelets are released from the bone marrow.
ANSWER: E
Rationale:
Abciximab is a chimeric human-murine monoclonal antibody Fab fragment (the antigen-binding fragment of the c7E3 IgG antibody) that binds the activated GP IIb/IIIa (glycoprotein IIb/IIIa, integrin alphaIIb beta3) receptor with very high affinity (dissociation constant approximately 5 nM) and extremely slow off-rate kinetics, making the binding functionally irreversible during clinical use. Although free plasma abciximab is cleared rapidly (plasma half-life 10 to 30 minutes), the receptor-bound drug on platelet surfaces persists for 14 to 21 days. Platelet function recovery occurs not through drug dissociation or elimination but because abciximab redistributes from heavily loaded inhibited platelets to newly released (uninhibited) platelets, diluting the per-platelet receptor blockade. Approximately 50% platelet function recovery occurs within 12 to 24 hours of stopping the infusion. For reversal of serious bleeding, platelet transfusion is effective because transfused platelets bind abciximab from plasma, restoring aggregation capacity.
Option A: Option A is incorrect: abciximab is a monoclonal antibody Fab fragment, not a small-molecule RGD mimetic; RGD mimetics describe eptifibatide (a cyclic peptide containing KGD, a related sequence) and tirofiban (a non-peptide mimetic).
Option B: Option B is incorrect: eptifibatide is the cyclic heptapeptide among this drug class; enterohepatic recirculation does not explain prolonged platelet-level effect and is not a mechanism relevant to any GP IIb/IIIa inhibitor.
Option C: Option C is incorrect: abciximab does not form a covalent bond with GP IIb/IIIa; covalent binding would describe irreversible agents like thienopyridine metabolites at P2Y12; furthermore, platelets are anucleate and cannot synthesize new GP IIb/IIIa.
Option D: Option D is incorrect: abciximab is not stored in platelet cytoplasm; the prolonged effect reflects platelet surface redistribution of the drug across the circulating platelet pool, not intracellular sequestration.
9. A 68-year-old woman with an NSTEMI (non-ST-elevation myocardial infarction) and an estimated creatinine clearance (CrCl) of 35 mL/min is being prepared for percutaneous coronary intervention (PCI). The interventional cardiologist is considering adding a glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor for procedural support. The team discusses eptifibatide, abciximab, and tirofiban. Which of the following statements regarding GP IIb/IIIa inhibitor dosing in renal impairment is correct?
A) Eptifibatide is primarily renally eliminated (approximately 50% excreted unchanged in urine); at a CrCl of 10 to 50 mL/min the infusion rate should be halved, and eptifibatide is contraindicated when CrCl is below 10 mL/min or in patients on dialysis.
B) Abciximab requires dose reduction to 50% of the standard infusion rate when CrCl falls below 50 mL/min because its Fab fragment undergoes significant renal catabolism, accumulating in patients with impaired glomerular filtration.
C) Tirofiban does not require dose adjustment in renal impairment because it is predominantly hepatically metabolized by CYP3A4, with renal excretion accounting for less than 10% of total drug elimination.
D) All three GP IIb/IIIa inhibitors require equivalent 50% infusion rate reductions at CrCl 30 to 50 mL/min because all three share comparable degrees of renal elimination as small-molecule synthetic compounds.
E) Eptifibatide is the only GP IIb/IIIa inhibitor that does not require renal dose adjustment because its cyclic peptide structure is cleaved by plasma proteases before renal filtration, eliminating the need for dose modification in moderate renal impairment.
ANSWER: A
Rationale:
Eptifibatide is a cyclic heptapeptide that is primarily renally eliminated, with approximately 50% of the drug excreted unchanged in the urine. In patients with a CrCl of 10 to 50 mL/min, the infusion rate should be halved (from 2 mcg/kg/min to 1 mcg/kg/min) because reduced renal clearance prolongs drug exposure and increases bleeding risk. Eptifibatide is contraindicated in patients with CrCl below 10 mL/min or in patients on dialysis. Tirofiban is also renally eliminated (approximately 65% excreted unchanged in urine) and requires a 50% infusion rate reduction when CrCl is below 30 mL/min; tirofiban is also contraindicated in dialysis patients. Abciximab, by contrast, does not require dose adjustment in renal impairment because it binds to platelets as a large Fab fragment and its clearance is not dependent on renal function.
Option B: Option B is incorrect: abciximab does not require renal dose adjustment; its disposition is dominated by platelet binding and redistribution, not by glomerular filtration of the intact Fab fragment.
Option C: Option C is incorrect: tirofiban is predominantly renally eliminated (approximately 65% unchanged in urine), not hepatically metabolized by CYP3A4; it does require dose adjustment at CrCl below 30 mL/min.
Option D: Option D is incorrect: the three agents have distinct elimination pathways and distinct renal dose adjustment thresholds — abciximab requires none, eptifibatide requires reduction at CrCl below 50 mL/min, and tirofiban at CrCl below 30 mL/min.
Option E: Option E is incorrect: eptifibatide does require renal dose adjustment; the premise that plasma protease cleavage eliminates the need for adjustment is incorrect — significant amounts of intact eptifibatide are excreted renally.
10. A 52-year-old man undergoes elective drug-eluting stent (DES) implantation for stable coronary artery disease and is started on clopidogrel 75 mg daily plus aspirin. Three months later he is found to have sub-acute stent thrombosis requiring repeat PCI. Pharmacogenomic testing reveals he carries two copies of the CYP2C19*2 loss-of-function allele, classifying him as a CYP2C19 poor metabolizer. The cardiologist explains to the resident why this genotype is clinically significant for clopidogrel therapy. Which of the following best describes the pharmacogenomic consequence of CYP2C19 poor metabolizer status in this patient?
A) CYP2C19*2 encodes an enzyme with enhanced clopidogrel bioactivation; poor metabolizers generate excessive active thiol metabolite, paradoxically increasing platelet inhibition to levels associated with spontaneous hemorrhage.
B) CYP2C19*2 is a gain-of-function allele present in approximately 20 to 30% of Europeans that increases clopidogrel bioactivation and active metabolite exposure, resulting in greater platelet inhibition and increased bleeding risk in this population.
C) CYP2C19*2 is a loss-of-function allele that reduces the first and second hepatic oxidation steps of clopidogrel bioactivation, reducing active thiol metabolite formation; because the first step is completely abolished, no active metabolite can be generated and platelet inhibition is completely absent.
D) CYP2C19*2 is a loss-of-function splice-site variant that reduces clopidogrel bioactivation by impairing the hepatic oxidation steps required to generate the active thiol metabolite; poor metabolizers have substantially reduced platelet inhibition and increased rates of major adverse cardiovascular events including stent thrombosis.
E) CYP2C19*2 reduces the hepatic inactivation of clopidogrel's active metabolite rather than its formation, prolonging active metabolite exposure but resulting in unexpected toxicity rather than reduced antiplatelet efficacy.
ANSWER: D
Rationale:
CYP2C19*2 is a splice-site variant (an intronic point mutation that creates an aberrant splice site, producing a truncated, non-functional protein) that is the most common CYP2C19 loss-of-function allele. Patients carrying one copy are classified as intermediate metabolizers and those with two copies (as in this case) as poor metabolizers. Because clopidogrel requires two sequential CYP-dependent oxidation steps — both of which rely substantially on CYP2C19 — poor metabolizers generate markedly less active thiol metabolite, resulting in inadequate P2Y12 inhibition and a substantially higher risk of major adverse cardiovascular events (MACE) including stent thrombosis, as demonstrated in TRITON-TIMI 38 substudy analyses and multiple retrospective cohort studies. The FDA issued a boxed warning for clopidogrel regarding poor metabolizer status in 2010. Current guidelines recommend switching such patients to prasugrel or ticagrelor when DAPT (dual antiplatelet therapy) is required after PCI.
Option A: Option A is incorrect: CYP2C19*2 is a loss-of-function, not gain-of-function variant; it reduces, not enhances, clopidogrel bioactivation.
Option B: Option B is incorrect: CYP2C19*17 (not CYP2C19*2) is the gain-of-function allele present in approximately 20 to 30% of Europeans, associated with greater clopidogrel bioactivation and potential increased bleeding risk.
Option C: Option C is incorrect: while poor metabolizer status substantially reduces active thiol formation, it does not completely abolish it; residual CYP3A4, CYP2B6, and CYP2C9 activity provide partial bioactivation; the result is reduced, not absent, platelet inhibition.
Option E: Option E is incorrect: CYP2C19 is involved in clopidogrel bioactivation (generating the active thiol), not in active metabolite inactivation; reduced function impairs formation of the active metabolite, not its degradation.
11. A 60-year-old man with a prior STEMI (ST-elevation myocardial infarction) treated with drug-eluting stent (DES) implantation one year ago has completed the initial 12 months of dual antiplatelet therapy (DAPT) with aspirin and ticagrelor without any bleeding complications. He has a history of diabetes mellitus, a prior myocardial infarction before this event, and his current ejection fraction is 38%. His cardiologist is considering whether to extend DAPT beyond 12 months. Which of the following risk tools is specifically designed to guide the decision to prolong DAPT beyond 12 months in patients who have already tolerated 12 months without bleeding?
A) The PRECISE-DAPT score, which uses five variables including creatinine clearance, hemoglobin, leukocyte count, age, and prior spontaneous bleeding to predict whether extending DAPT will reduce bleeding risk at the 12-month mark.
B) The DAPT Score, which incorporates clinical variables including age, diabetes mellitus, prior MI, CHF or reduced ejection fraction, and stent-related factors to estimate the net ischemic benefit of extending DAPT beyond 12 months in patients who have tolerated the initial period without bleeding.
C) The GRACE (Global Registry of Acute Coronary Events) score, which stratifies 6-month mortality risk after ACS and is used to determine DAPT duration as a function of predicted 6-month survival.
D) The HAS-BLED score, originally developed for atrial fibrillation anticoagulation decisions, which has been validated in the post-PCI DAPT context to identify patients at sufficient bleeding risk to warrant discontinuing DAPT at 12 months.
E) The TIMI (Thrombolysis in Myocardial Infarction) Risk Score, which assigns points for prior thrombotic events and cardiac biomarkers, with a score above 5 identifying patients who benefit from DAPT extension beyond 24 months.
ANSWER: B
Rationale:
The DAPT Score was developed specifically from the DAPT trial to identify patients who would benefit from prolonged DAPT (beyond 12 months) after drug-eluting stent implantation. It incorporates nine clinical variables including age, diabetes mellitus, current smoker status, prior PCI (percutaneous coronary intervention) or MI, CHF (congestive heart failure) or left ventricular ejection fraction below 30%, MI at the time of the stent procedure, vein graft stenting, stent diameter, and paclitaxel-eluting stent use. A score of 2 or above favors extended DAPT due to net ischemic benefit, while a score below 2 suggests that prolongation does not offer net benefit over the associated bleeding risk. This patient has several high-score features (diabetes, prior MI, reduced EF). The DAPT Score is specifically used in patients who have already tolerated 12 months of DAPT without bleeding events, as a tool for deciding extension, not initiation.
Option A: Option A is incorrect: the PRECISE-DAPT score estimates bleeding risk and is used to guide the decision to shorten DAPT duration (scores of 25 or above favor 3 to 6 months); it does not guide DAPT prolongation beyond 12 months.
Option C: Option C is incorrect: the GRACE score predicts short-term mortality after ACS and is used for risk stratification and management intensity decisions, not for DAPT duration.
Option D: Option D is incorrect: HAS-BLED was developed for anticoagulation decisions in atrial fibrillation and has not been validated as the primary tool for DAPT duration decisions in the post-PCI setting; the PRECISE-DAPT score is the validated tool for bleeding risk in the PCI-DAPT context.
Option E: Option E is incorrect: the TIMI Risk Score stratifies risk in ACS at presentation and predicts 14-day MACE but is not a DAPT duration decision tool.
12. A 58-year-old woman with an NSTEMI (non-ST-elevation myocardial infarction) and preserved left ventricular function is started on ticagrelor 90 mg twice daily plus aspirin after PCI (percutaneous coronary intervention) with drug-eluting stent placement. Two weeks later she reports episodic shortness of breath that occurs at rest and is not associated with exertion, chest pain, or orthopnea. Her echocardiogram and brain natriuretic peptide (BNP) are unchanged from baseline, and her lung examination is clear. Which of the following best explains the mechanism underlying this adverse effect?
A) Ticagrelor binds the adenosine A1 receptor on pulmonary mast cells, triggering histamine release and producing reversible bronchoconstriction that is distinct from classic aspirin-exacerbated respiratory disease.
B) Ticagrelor's active metabolite AR-C124910XX accumulates in pulmonary capillary endothelium, where it inhibits angiotensin-converting enzyme (ACE) and produces a bradykinin-mediated cough and dyspnea syndrome similar to ACE inhibitor-induced cough.
C) Ticagrelor inhibits equilibrative nucleoside transporter 1 (ENT1), the cellular adenosine reuptake transporter, increasing local adenosine concentrations; elevated adenosine stimulates pulmonary vagal C-fiber afferents via A2A and A1 receptors, producing dyspnea that is not bronchospasm or heart failure.
D) Ticagrelor causes a class-specific platelet desensitization effect that reduces TXA2-mediated pulmonary vasoconstriction, resulting in transient ventilation-perfusion mismatch and episodic dyspnea in approximately 13 to 15% of patients.
E) Ticagrelor produces subclinical left ventricular dysfunction by inhibiting myocardial P2Y12 receptors involved in cardioprotective signaling; the resulting diastolic dysfunction produces dyspnea at rest without overt heart failure markers on early echocardiography.
ANSWER: C
Rationale:
Ticagrelor inhibits equilibrative nucleoside transporter 1 (ENT1), the major cellular adenosine reuptake transporter present on platelets, erythrocytes, and endothelial cells. This mechanism is shared by ticagrelor's active metabolite AR-C124910XX and results in accumulation of extracellular adenosine at pharmacological concentrations in tissues where ticagrelor concentrations are high. In the pulmonary circulation, elevated adenosine stimulates vagal C-fiber afferents (unmyelinated sensory neurons in the lung parenchyma and airways) through adenosine receptors, generating a sensation of dyspnea that is not associated with bronchospasm, airflow obstruction, or heart failure. This dyspnea occurs in approximately 13 to 15% of patients and is typically mild, episodic, and self-limiting; it does not require drug discontinuation in most cases and tends to diminish with continued use. The absence of echocardiographic change and normal BNP in this patient are reassuring and consistent with this ticagrelor-specific mechanism.
Option A: Option A is incorrect: ticagrelor does not bind adenosine A1 receptors on pulmonary mast cells or trigger histamine-mediated bronchoconstriction; this does not resemble aspirin-exacerbated respiratory disease.
Option B: Option B is incorrect: ticagrelor's active metabolite does not inhibit ACE; ACE inhibitor cough is mediated by bradykinin accumulation, which is a distinct mechanism unrelated to ticagrelor.
Option D: Option D is incorrect: TXA2 reduction is the mechanism of aspirin, not ticagrelor; ticagrelor's dyspnea is not related to pulmonary vasoconstriction or ventilation-perfusion mismatch.
Option E: Option E is incorrect: there is no established evidence that ticagrelor inhibits myocardial P2Y12 receptors or produces diastolic dysfunction; the dyspnea mechanism is adenosine-mediated stimulation of pulmonary afferents.
13. A 66-year-old man with a prior myocardial infarction (MI) three years ago and peripheral arterial disease (PAD) is being evaluated for secondary prevention optimization. He has been on aspirin 81 mg daily and atorvastatin. His cardiologist considers adding vorapaxar to his regimen. His past medical history also includes an ischemic stroke five years ago with full neurological recovery. Which of the following is the most critical contraindication to vorapaxar in this patient?
A) His diagnosis of peripheral arterial disease (PAD), for which vorapaxar has no established safety data and which represents an unlabeled and unapproved indication associated with markedly elevated intracranial hemorrhage risk.
B) His age of 66 years and male sex, which together increase the absolute risk of vorapaxar-related intracranial hemorrhage to a level that exceeds any cardiovascular benefit in the TRA 2°P-TIMI 50 trial subgroup analysis.
C) His concurrent aspirin use, because vorapaxar combined with aspirin produces a pharmacodynamic interaction at PAR-1 and COX-1 simultaneously, increasing intracranial hemorrhage through dual upstream platelet pathway blockade.
D) His history of prior myocardial infarction, which paradoxically increases intracranial hemorrhage risk with vorapaxar through the mechanism of PAR-1-mediated fibrinolytic suppression, outweighing ischemic benefit in this population.
E) His history of prior ischemic stroke, which is an absolute contraindication to vorapaxar based on net harm (markedly elevated intracranial hemorrhage) demonstrated in the TRA 2°P-TIMI 50 trial, regardless of time elapsed since the stroke.
ANSWER: E
Rationale:
Prior stroke or transient ischemic attack (TIA) is an absolute contraindication to vorapaxar, regardless of how much time has elapsed since the event. In the TRA 2°P-TIMI 50 trial (n = 26,449), the subgroup of patients with prior stroke or TIA who received vorapaxar had markedly elevated rates of intracranial hemorrhage that produced net harm: the bleeding risk far outweighed any ischemic benefit in this subgroup. This finding is reflected in vorapaxar's FDA-approved prescribing information as a boxed warning and formal contraindication. In patients with prior MI but no history of stroke or TIA (as was also analyzed in TRA 2°P-TIMI 50), vorapaxar 2.5 mg daily added to standard antiplatelet therapy reduced recurrent MI and stent thrombosis with a more acceptable benefit-to-risk ratio. For this patient, despite having both a prior MI and PAD (each an approved indication), the history of prior ischemic stroke makes vorapaxar absolutely contraindicated.
Option A: Option A is incorrect: PAD is actually one of vorapaxar's two approved indications (prior MI and PAD); PAD is not a contraindication.
Option B: Option B is incorrect: age 66 and male sex are not independent contraindications to vorapaxar; the absolute contraindication is prior stroke or TIA, not demographic characteristics.
Option C: Option C is incorrect: while vorapaxar is used in combination with aspirin (and this combination does increase bleeding risk), the concurrent aspirin use is not in itself a contraindication; the combination is the standard approved use.
Option D: Option D is incorrect: prior myocardial infarction is one of the approved indications for vorapaxar, not a contraindication; PAR-1-mediated fibrinolytic suppression is not a recognized mechanism of vorapaxar-related intracranial hemorrhage.
14. A 72-year-old man with intermittent claudication due to peripheral arterial disease is referred for pharmacological management. His resting ankle-brachial index (ABI) is 0.62, and he experiences calf pain after walking approximately one block. His other medical history includes well-controlled hypertension and an echocardiogram from six months ago showing an ejection fraction of 42% with mild diastolic dysfunction, classified as HFpEF (heart failure with preserved ejection fraction). His current medications are aspirin, lisinopril, and amlodipine. The vascular medicine team considers cilostazol for his claudication. Which of the following represents the most important contraindication in this patient?
A) His heart failure with preserved ejection fraction (HFpEF), because cilostazol inhibits phosphodiesterase type 3 (PDE3) in cardiac myocytes as well as platelets and smooth muscle; PDE3 inhibition in the heart increases myocardial cAMP (cyclic AMP), producing inotropic and proarrhythmic effects that have been associated with increased mortality in chronic heart failure trials involving PDE3 inhibitors.
B) His concurrent aspirin use, because cilostazol and aspirin produce pharmacodynamic synergy at COX-1 that substantially increases gastrointestinal hemorrhage risk when combined, representing a formally contraindicated drug combination.
C) His concurrent amlodipine use, because amlodipine is a strong CYP3A4 inhibitor that markedly increases cilostazol plasma concentrations, producing fatal arrhythmias at standard doses; dose reduction to 50 mg twice daily is required when CYP3A4 inhibitors are co-administered.
D) His hypertension, because cilostazol's vasodilatory mechanism produces rebound hypertension when discontinued abruptly, and the resulting blood pressure surge is particularly hazardous in patients already on antihypertensive therapy.
E) His age of 72 years, because cilostazol is formally contraindicated in patients older than 70 years due to accumulation of its active sulfone metabolite in elderly patients with age-related decline in hepatic blood flow.
ANSWER: A
Rationale:
Cilostazol is a selective phosphodiesterase type 3 (PDE3) inhibitor that increases intracellular cyclic AMP (cAMP) in platelets, vascular smooth muscle cells, and cardiac myocytes. While elevated cAMP in platelets and vascular smooth muscle produces the desired antiplatelet and vasodilatory effects that make cilostazol effective for intermittent claudication, elevated cAMP in cardiac myocytes produces positive inotropic and chronotropic effects along with proarrhythmic potential. Milrinone and enoximone, which are also PDE3 inhibitors, demonstrated increased all-cause mortality in chronic heart failure trials despite short-term hemodynamic improvement, establishing that PDE3 inhibition is harmful in the setting of chronic heart failure. Cilostazol is therefore contraindicated in heart failure of any severity — including HFpEF, as in this patient — regardless of whether the ejection fraction is preserved or reduced. This is the most important contraindication for this patient.
Option B: Option B is incorrect: aspirin and cilostazol combination is not formally contraindicated; they are commonly co-prescribed in vascular patients; the pharmacodynamic interaction does not constitute a contraindicated combination.
Option C: Option C is incorrect: amlodipine is not a strong CYP3A4 inhibitor; it is a CYP3A4 substrate and weak inhibitor; cilostazol dose reduction to 50 mg twice daily is recommended with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, and certain macrolide antibiotics.
Option D: Option D is incorrect: cilostazol does not cause rebound hypertension on discontinuation; its vasodilatory effect simply wanes as drug levels decline.
Option E: Option E is incorrect: age above 70 years is not a formal contraindication to cilostazol; there is no age-specific contraindication in the prescribing information; dose adjustment for elderly patients is guided by renal and hepatic function, not age alone.
15. A 61-year-old man undergoes PCI (percutaneous coronary intervention) for a high-risk NSTEMI (non-ST-elevation myocardial infarction) and is given abciximab. Approximately 4 hours after starting the infusion, the nursing staff notes that his platelet count has dropped from a pre-procedure baseline of 210,000/mcL to 28,000/mcL. He has no current bleeding and his heparin infusion has been stopped. The team diagnoses acute profound thrombocytopenia related to abciximab. Which of the following best describes the mechanism underlying this class-specific adverse effect of GP IIb/IIIa inhibitors?
A) The GP IIb/IIIa inhibitors directly activate complement via the classical pathway when bound to the platelet surface, producing complement-mediated platelet lysis and acute thrombocytopenia that is mechanistically identical to drug-induced immune thrombocytopenic purpura.
B) Abciximab's murine-derived Fab sequences are recognized by pre-formed anti-mouse antibodies in approximately 0.5 to 2% of patients, triggering antibody-dependent cellular cytotoxicity (ADCC) that destroys abciximab-coated platelets in the reticuloendothelial system.
C) GP IIb/IIIa inhibitor-induced thrombocytopenia results from direct platelet toxicity caused by the inhibitors competing with fibrinogen for GP IIb/IIIa binding; at high drug concentrations, this competitive displacement induces platelet membrane disruption and intravascular fragmentation.
D) Naturally occurring antibodies in some patients recognize ligand-induced binding site (LIBS) neoepitopes on the GP IIb/IIIa complex that are exposed only when the inhibitor occupies the receptor, triggering antibody-mediated platelet destruction that can occur without prior exposure to the drug.
E) GP IIb/IIIa inhibitor-associated thrombocytopenia is caused by the inhibitor binding the vitronectin receptor (integrin alphav beta3) on megakaryocytes rather than mature platelets, suppressing thrombopoiesis and producing a delayed thrombocytopenia at 5 to 7 days similar to heparin-induced thrombocytopenia type I.
ANSWER: D
Rationale:
GP IIb/IIIa inhibitor-associated thrombocytopenia is a class-specific immune mechanism involving pre-formed naturally occurring antibodies that recognize ligand-induced binding site (LIBS) neoepitopes — structural conformational changes in the GP IIb/IIIa complex (integrin alphaIIb beta3) that are exposed only when the inhibitor occupies the receptor's binding site. These antibodies are present in the circulation of some individuals prior to any drug exposure, explaining why the thrombocytopenia can occur on the very first administration (without sensitization through prior exposure). When the GP IIb/IIIa inhibitor binds and exposes the LIBS neoepitope, the pre-formed antibody recognizes and binds it, triggering Fc receptor-mediated clearance of the antibody-coated platelets by the reticuloendothelial system. The thrombocytopenia typically develops within 2 to 24 hours of drug initiation and is generally reversible within 2 to 5 days of stopping the agent. This mechanism is distinct from heparin-induced thrombocytopenia (HIT) in both timing and pathophysiology, though both require monitoring with complete blood counts.
Option A: Option A is incorrect: complement-mediated platelet lysis is not the established mechanism; the LIBS neoepitope antibody mechanism is distinct from complement activation pathways.
Option B: Option B is incorrect: while abciximab is a chimeric human-murine Fab fragment, the thrombocytopenia mechanism is LIBS neoepitope-mediated and occurs with all three GP IIb/IIIa inhibitors including the non-antibody small molecules eptifibatide and tirofiban; it is not driven by anti-mouse antibody recognition of the chimeric Fab sequences.
Option C: Option C is incorrect: the thrombocytopenia is immune-mediated, not a result of direct membrane disruption from competitive fibrinogen displacement.
Option E: Option E is incorrect: the thrombocytopenia is not megakaryocyte suppression; it is an immune destruction of circulating platelets; it occurs within hours, not 5 to 7 days, and has no mechanistic resemblance to HIT type I, which is a non-immune, mild thrombocytopenia.
16. A vascular biology researcher is explaining the sequence of platelet adhesion to a group of cardiology fellows. She notes that the initial step of platelet tethering to an injured vessel wall at high arterial shear rates is distinct from the stable adhesion that follows and is mediated by a different receptor-ligand pair. Which of the following correctly identifies the receptor on the platelet surface and its ligand that mediate the initial tethering and rolling phase of platelet adhesion under high-shear conditions?
A) Integrin alpha-2 beta-1 (GP Ia/IIa) on the platelet surface binds directly to exposed subendothelial collagen, initiating tethering at high shear rates; this adhesion is dependent on divalent cation coordination but is independent of von Willebrand factor.
B) Glycoprotein Ib-IX-V (GP Ib-IX-V) on the platelet surface binds von Willebrand factor (vWF) immobilized on exposed subendothelial collagen, mediating the initial reversible tethering and rolling of platelets along the injured vessel wall at high shear rates.
C) Glycoprotein VI (GP VI) on the platelet surface binds von Willebrand factor (vWF) multimers in the flowing plasma, providing the initial high-shear tethering required before collagen-mediated firm adhesion can proceed.
D) Integrin alphaIIb beta3 (GP IIb/IIIa) constitutively binds collagen-anchored fibronectin at the injured vessel wall, initiating platelet tethering before inside-out signaling activates GP IIb/IIIa for high-affinity fibrinogen binding.
E) P-selectin expressed on activated endothelial cells interacts with P-selectin glycoprotein ligand-1 (PSGL-1) on platelet surfaces to mediate initial rolling of platelets along the injured endothelium, analogous to the leukocyte-endothelium rolling interaction.
ANSWER: B
Rationale:
Under the high shear conditions that characterize small arteries and atherosclerotic stenoses, platelet adhesion to the injured vessel wall is initiated by GP Ib-IX-V (glycoprotein Ib-IX-V) on the platelet surface binding to von Willebrand factor (vWF) immobilized on exposed subendothelial collagen at the site of injury. This interaction is the physiologically correct high-shear tethering mechanism: GP Ib-IX-V and vWF have a fast on-rate and fast off-rate that allows reversible platelet tethering and rolling along the damaged surface. The shear force itself promotes this interaction by inducing a conformational change in plasma vWF multimers that exposes the GP Ib binding site (the A1 domain of vWF). After tethering, firmer adhesion is established through GP VI (glycoprotein VI) and integrin alpha-2 beta-1 (GP Ia/IIa), which bind directly to exposed collagen fibers and generate the activation signals that trigger the full platelet activation cascade.
Option A: Option A is incorrect: integrin alpha-2 beta-1 mediates firm adhesion to collagen after the initial tethering step but is not responsible for the initial high-shear tethering; it does not provide the rapid, reversible rolling interaction.
Option C: Option C is incorrect: GP VI binds collagen directly, not vWF; it is the major collagen activation signaling receptor on platelets (signaling through Syk kinase), not the initial tethering receptor under high shear.
Option D: Option D is incorrect: GP IIb/IIIa (integrin alphaIIb beta3) is inactive (low-affinity conformation) on resting platelets and does not constitute the initial tethering receptor; it mediates aggregation after inside-out activation.
Option E: Option E is incorrect: P-selectin is expressed on activated platelets (released from alpha-granules) and activated endothelium, and does participate in platelet-leukocyte interactions, but it does not mediate the initial high-shear platelet tethering to the injured vessel wall that initiates thrombus formation.
17. A 59-year-old man undergoes PCI (percutaneous coronary intervention) for a STEMI (ST-elevation myocardial infarction) and receives cangrelor as the procedural P2Y12 inhibitor because he was unable to receive oral pre-loading. The cardiologist plans to transition him to ticagrelor 90 mg twice daily for long-term post-PCI DAPT (dual antiplatelet therapy). The fellow asks when ticagrelor should be given relative to the cangrelor infusion. In a second scenario, a different patient on the same day receives cangrelor during PCI and is to be transitioned to clopidogrel 75 mg daily. Which of the following correctly describes the timing rules for transitioning from cangrelor to both oral agents?
A) Both clopidogrel and ticagrelor must be administered after the cangrelor infusion ends, because cangrelor occupies the P2Y12 active binding site on all surface receptor copies and blocks the binding of any oral P2Y12 antagonist while the infusion is running.
B) Both clopidogrel and ticagrelor can be administered during the cangrelor infusion, because cangrelor's reversible binding is rapidly displaced by either oral agent, allowing seamless transition without a gap in platelet inhibition.
C) Ticagrelor can be administered during the cangrelor infusion and will achieve effective platelet inhibition when cangrelor levels decline, because ticagrelor binds an allosteric site and does not compete with cangrelor for the ADP binding site; clopidogrel and prasugrel must be administered after the cangrelor infusion ends, because their active thiol metabolites bind the same P2Y12 active site that cangrelor occupies, and concurrent cangrelor would block this binding.
D) Clopidogrel can be given during the infusion because cangrelor accelerates CYP2C19-mediated bioactivation of the clopidogrel prodrug; ticagrelor must wait until after the infusion ends because cangrelor's reversible binding at the allosteric site creates steric interference with ticagrelor's binding geometry.
E) Neither clopidogrel nor ticagrelor should be given until at least 4 hours after the cangrelor infusion ends, because rapid P2Y12 receptor switching during the period of receptor redistribution produces paradoxical platelet hyperactivation through receptor sensitization.
ANSWER: C
Rationale:
The transition timing from cangrelor to oral P2Y12 inhibitors depends critically on the binding site used by each agent. Cangrelor occupies the ADP (adenosine diphosphate) orthosteric binding site on P2Y12. The thienopyridine active metabolites (from clopidogrel and prasugrel) also require access to a cysteine residue near the ADP binding site to form their irreversible disulfide bond; while cangrelor is present and occupying the receptor, the thienopyridine active metabolite cannot access its binding site, meaning no irreversible covalent inactivation of P2Y12 occurs during the infusion. If clopidogrel or prasugrel is given during the cangrelor infusion, the platelet inhibition gap that would occur at cangrelor offset (60 to 90 minutes after stopping) is not bridged by the thienopyridine, because the irreversible binding never happened. Therefore, clopidogrel and prasugrel loading doses must be administered after the cangrelor infusion is stopped. In contrast, ticagrelor binds an allosteric site on P2Y12 that is distinct from the ADP binding site; it does not compete with cangrelor for the same binding domain. Ticagrelor can therefore be given during the cangrelor infusion, and when cangrelor levels decline, ticagrelor (already absorbed and distributing) provides continuous platelet inhibition without a gap.
Option A: Option A is incorrect: while it is true that clopidogrel and prasugrel must be given after the infusion ends, ticagrelor can be given during the infusion — the two agents have different transition rules based on their distinct binding sites.
Option B: Option B is incorrect: clopidogrel and prasugrel cannot be effectively given during the infusion because cangrelor blocks their active metabolites' binding; only ticagrelor can overlap.
Option D: Option D is incorrect: cangrelor does not accelerate CYP2C19 bioactivation of clopidogrel; and ticagrelor's allosteric site does not compete with cangrelor, making simultaneous administration appropriate for ticagrelor.
Option E: Option E is incorrect: there is no clinical evidence of paradoxical platelet hyperactivation during the transition period, and the 4-hour delay would create an unacceptably long window of inadequate P2Y12 inhibition after cangrelor cessation.
18. An interventional cardiology fellow is preparing a journal club presentation comparing the TRITON-TIMI 38 and PLATO trials. She notes that both trials demonstrated superiority of a newer P2Y12 inhibitor over clopidogrel in ACS (acute coronary syndrome) patients, but the trials differed in important ways in terms of the population studied, the primary endpoint, and the mortality outcomes. Regarding the PLATO trial specifically, which of the following most accurately describes its design and primary finding?
A) In the PLATO trial (n = 18,624), ticagrelor 90 mg twice daily versus clopidogrel 75 mg daily in patients with ACS (managed both with and without PCI) significantly reduced the primary composite endpoint of cardiovascular death, MI, or stroke, with all-cause mortality also significantly reduced and without a significant increase in total major bleeding.
B) In the PLATO trial (n = 18,624), ticagrelor 60 mg twice daily versus clopidogrel 600 mg loading in patients with ACS undergoing mandatory PCI significantly reduced stent thrombosis, but ticagrelor showed no significant reduction in cardiovascular death compared to clopidogrel.
C) In the PLATO trial, prasugrel versus clopidogrel in ACS patients undergoing PCI reduced the primary composite of cardiovascular death, MI, or stroke by 19%, with a significant reduction in stent thrombosis but a significant increase in major bleeding including fatal and intracranial hemorrhage.
D) In the PLATO trial, ticagrelor versus clopidogrel in stable coronary artery disease patients undergoing elective PCI demonstrated equivalent ischemic outcomes but superior bleeding safety, supporting ticagrelor as the preferred agent for elective procedures.
E) In the PLATO trial, ticagrelor produced an unexpected increase in overall mortality in the North American patient subgroup, leading the FDA to require a post-marketing trial confirming ticagrelor's net clinical benefit before approving it as first-line therapy for ACS.
ANSWER: A
Rationale:
The PLATO (Platelet Inhibition and Patient Outcomes) trial randomized 18,624 patients with ACS (including both STEMI and NSTEMI/UA, managed with or without PCI) to ticagrelor 90 mg twice daily or clopidogrel 75 mg daily. Ticagrelor significantly reduced the primary composite endpoint of cardiovascular death, MI (myocardial infarction), or stroke at 12 months (9.8% vs. 11.7%, hazard ratio 0.84). Critically, cardiovascular mortality was significantly reduced (4.0% vs. 5.1%), and all-cause mortality was also significantly reduced — a finding that distinguished PLATO from TRITON-TIMI 38, where mortality reduction was less clear. TIMI major bleeding was not significantly different between the two groups (though non-CABG [coronary artery bypass grafting]-related bleeding was higher with ticagrelor), and intracranial hemorrhage was not significantly increased. The unique class-specific adverse effects of ticagrelor in PLATO included dyspnea (approximately 13 to 15% of patients) and asymptomatic ventricular pauses.
Option B: Option B is incorrect: the PLATO ticagrelor dose was 90 mg twice daily (not 60 mg, which is the secondary prevention dose for patients with prior MI more than one year earlier); the trial did not mandate PCI and included medically managed patients.
Option C: Option C is incorrect: the trial describing prasugrel versus clopidogrel with 19% relative risk reduction in the primary composite, stent thrombosis reduction, and increased major bleeding was TRITON-TIMI 38, not PLATO.
Option D: Option D is incorrect: PLATO enrolled ACS patients, not stable coronary artery disease undergoing elective PCI; the trial was not a comparison in elective PCI.
Option E: Option E is incorrect: while a North American subgroup showed less benefit for ticagrelor in PLATO (attributed partly to the higher aspirin doses used in North America), the FDA did approve ticagrelor based on the overall trial data; ticagrelor is an approved first-line agent for ACS management.
19. A 70-year-old man with paroxysmal atrial fibrillation (AF) on apixaban for stroke prevention undergoes percutaneous coronary intervention (PCI) with drug-eluting stent placement for an NSTEMI (non-ST-elevation myocardial infarction). The team discusses post-PCI antithrombotic management. They must balance AF stroke prevention, stent thrombosis prevention, and bleeding risk. The AUGUSTUS trial is cited. Which of the following best describes the default antithrombotic strategy supported by AUGUSTUS and current ACC/AHA (American College of Cardiology/American Heart Association) guidelines for most AF patients after PCI, following a brief initial period of triple therapy?
A) Aspirin 81 mg plus clopidogrel 75 mg (DAPT without anticoagulation), because the AUGUSTUS trial demonstrated that adding an oral anticoagulant (OAC) to DAPT did not reduce AF stroke risk in the post-PCI population and significantly increased bleeding without benefit.
B) Vitamin K antagonist (warfarin) plus aspirin 81 mg, because the AUGUSTUS trial demonstrated that warfarin-based triple therapy with aspirin was superior to DOAC (direct oral anticoagulant)-based regimens in preventing stent thrombosis in the first 12 months after PCI.
C) Rivaroxaban 2.5 mg twice daily plus DAPT (aspirin plus clopidogrel) for 12 months, because the AUGUSTUS trial specifically validated this three-drug combination as the optimal antithrombotic regimen for AF patients undergoing PCI.
D) Apixaban plus aspirin 81 mg (without a P2Y12 inhibitor), because the AUGUSTUS trial demonstrated that adding a P2Y12 inhibitor to OAC plus aspirin did not reduce stent thrombosis and only increased bleeding risk; aspirin provides sufficient platelet inhibition in the post-PCI period.
E) Oral anticoagulant (preferring a DOAC over warfarin) plus a P2Y12 inhibitor (preferring clopidogrel), without aspirin, for most AF patients after PCI following an initial brief period of triple therapy; AUGUSTUS demonstrated that apixaban-based dual therapy was safer than warfarin-based therapy and that adding aspirin to OAC plus P2Y12 inhibitor doubled bleeding events without reducing ischemia.
ANSWER: E
Rationale:
The AUGUSTUS trial (Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation, n = 4,614) used a 2×2 factorial design to compare apixaban versus warfarin AND aspirin versus placebo in AF patients undergoing PCI or with ACS. Key findings were: (1) apixaban produced significantly less bleeding than warfarin-based therapy without compromising ischemic outcomes, supporting DOAC preference over warfarin; and (2) adding aspirin to OAC plus P2Y12 inhibitor doubled clinically relevant bleeding events (16.1% vs. 9.0%) without reducing the composite ischemic endpoint, supporting aspirin omission. The recommended default strategy per ACC/AHA guidelines is therefore OAC (preferring DOAC, specifically apixaban in AUGUSTUS) plus a P2Y12 inhibitor (preferring clopidogrel given the data and bleeding profile) without aspirin for most patients, after an initial 1 to 4 weeks of triple therapy in the highest stent thrombosis risk period.
Option A: Option A is incorrect: omitting the OAC entirely is not supported; AF stroke risk requires ongoing anticoagulation regardless of the PCI indication; dual antiplatelet without OAC does not adequately address AF stroke risk.
Option B: Option B is incorrect: AUGUSTUS demonstrated that apixaban was superior to warfarin, not that warfarin-based triple therapy was superior; warfarin is no longer the preferred OAC in this setting.
Option C: Option C is incorrect: the AUGUSTUS trial did not validate rivaroxaban 2.5 mg twice daily plus DAPT; the rivaroxaban vascular dose was studied in the COMPASS trial for a different indication; AUGUSTUS specifically evaluated apixaban versus warfarin.
Option D: Option D is incorrect: AUGUSTUS demonstrated the benefit of a P2Y12 inhibitor (clopidogrel was most commonly used) as part of the dual therapy; P2Y12 inhibition is essential after PCI stent implantation, and dropping it in favor of aspirin alone is not the guideline-supported approach.
20. A 78-year-old woman with a history of prior spontaneous gastrointestinal bleeding undergoes elective PCI (percutaneous coronary intervention) with a new-generation drug-eluting stent for stable coronary artery disease. Her pre-procedure creatinine clearance (CrCl) is 32 mL/min, hemoglobin is 10.8 g/dL, and white blood cell count is 9.2 × 10⁹/L. The interventional cardiologist calculates her PRECISE-DAPT score and obtains a value of 31. Which of the following best describes the clinical implication of this score?
A) A PRECISE-DAPT score of 31 identifies this patient as at high ischemic risk based on her clinical profile; per validated score thresholds, she should receive DAPT (dual antiplatelet therapy) for 24 months rather than the standard 12 months to reduce late stent thrombosis.
B) A PRECISE-DAPT score of 31 indicates an intermediate risk for both ischemia and bleeding, supporting standard 12-month DAPT duration with a plan to reassess using the DAPT Score at 12 months to guide possible prolongation.
C) A PRECISE-DAPT score of 31 specifically identifies patients at high risk for CYP2C19-related clopidogrel resistance; per the validated threshold, genotype-guided P2Y12 inhibitor selection is recommended when PRECISE-DAPT is above 25.
D) A PRECISE-DAPT score of 31, which exceeds the validated threshold of 25, identifies this patient as at high bleeding risk; per score guidance, short-course DAPT of 3 to 6 months is preferable to standard or extended DAPT in patients with new-generation drug-eluting stents.
E) A PRECISE-DAPT score of 31 is below the clinical action threshold of 35; scores between 25 and 35 represent an indeterminate zone in which neither extended nor shortened DAPT duration is supported, and the DAPT Score should be used as the primary decision tool instead.
ANSWER: D
Rationale:
The PRECISE-DAPT (Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy) score was developed and validated to predict bleeding risk at 12 months in patients undergoing PCI with stent implantation. It incorporates five variables: age, creatinine clearance, hemoglobin, white blood cell count, and prior spontaneous bleeding. A score of 25 or above identifies patients at high bleeding risk for whom short-course DAPT (3 to 6 months) is the preferred strategy, particularly when a new-generation drug-eluting stent has been implanted (which has lower rates of late thrombosis than older-generation stents). This patient's score of 31, driven by her reduced CrCl, low hemoglobin, advanced age, and prior spontaneous gastrointestinal bleeding, exceeds the threshold of 25 and supports shortened DAPT rather than standard 12-month or extended DAPT.
Option A: Option A is incorrect: PRECISE-DAPT specifically predicts bleeding risk and supports shortened DAPT; a score above 25 supports shorter, not longer, DAPT duration; the tool for identifying patients who benefit from prolonged DAPT is the DAPT Score.
Option B: Option B is incorrect: a PRECISE-DAPT score of 31 is not in an indeterminate range; it clearly exceeds the 25 threshold that supports shortened DAPT; the score is not designed to be combined with the DAPT Score in this way.
Option C: Option C is incorrect: PRECISE-DAPT does not incorporate or identify CYP2C19 genotype risk; pharmacogenomic guidance for P2Y12 inhibitor selection is addressed by CYP2C19 testing, not by PRECISE-DAPT.
Option E: Option E is incorrect: there is no validated indeterminate zone between 25 and 35 in the PRECISE-DAPT scoring system; the validated action threshold is a score of 25 or above, which is the threshold this patient exceeds.
21. A 62-year-old woman weighing 54 kg with no history of stroke or TIA (transient ischemic attack) presents with an NSTEMI (non-ST-elevation myocardial infarction) and undergoes PCI (percutaneous coronary intervention) with drug-eluting stent placement. She is a CYP2C19 intermediate metabolizer. The cardiologist decides to use prasugrel for post-PCI DAPT (dual antiplatelet therapy) and begins with a 60 mg loading dose. Which of the following best describes the appropriate maintenance dose adjustment and the reason for it?
A) Prasugrel maintenance dosing does not require weight-based adjustment; the standard 10 mg daily dose is appropriate for all patients regardless of body weight, because prasugrel bioactivation is a hepatic process that depends on liver mass rather than total body weight.
B) The standard prasugrel maintenance dose should be reduced to 5 mg daily in this patient because she weighs less than 60 kg; in the TRITON-TIMI 38 trial, patients weighing less than 60 kg on standard-dose prasugrel showed no net clinical benefit compared to clopidogrel due to excess bleeding risk, and dose reduction to 5 mg daily is recommended to improve the benefit-to-risk ratio.
C) Because this patient is a CYP2C19 intermediate metabolizer, her prasugrel maintenance dose should be increased to 15 mg daily to compensate for the partial CYP2C19-mediated bioactivation step that generates reduced active metabolite levels compared to normal metabolizers.
D) Prasugrel maintenance dose requires reduction to 5 mg daily in all women regardless of weight, because sex-based pharmacokinetic differences produce greater active metabolite exposure in women at standard doses, conferring equivalent platelet inhibition at half the dose.
E) Prasugrel maintenance dose should be halved to 5 mg daily in this patient because her CrCl (creatinine clearance) of 45 mL/min places her in the moderate renal impairment category, where prasugrel active metabolite clearance is reduced by the renal route, requiring dose adjustment.
ANSWER: B
Rationale:
In the TRITON-TIMI 38 trial pre-specified subgroup analysis, patients weighing less than 60 kg on standard-dose prasugrel (10 mg daily maintenance) showed no net clinical benefit compared to clopidogrel — the reduction in ischemic events was offset by excess major bleeding, yielding no overall net clinical advantage at the standard dose. Current prescribing guidelines and the FDA label for prasugrel recommend consideration of dose reduction to 5 mg daily maintenance for patients weighing less than 60 kg to improve the benefit-to-risk ratio by reducing bleeding risk while maintaining meaningful platelet inhibition. The 60 mg loading dose is not adjusted for body weight in this scenario. This patient at 54 kg falls below the 60 kg threshold, making the 5 mg daily maintenance dose appropriate. Note that her CYP2C19 intermediate metabolizer status is not relevant to prasugrel dosing, as prasugrel's bioactivation is substantially less dependent on CYP2C19 than clopidogrel's.
Option A: Option A is incorrect: prasugrel dosing does require consideration of body weight for maintenance dosing; the prescribing information explicitly addresses the less-than-60 kg subgroup based on TRITON-TIMI 38 data.
Option C: Option C is incorrect: CYP2C19 genotype does not affect prasugrel bioactivation sufficiently to require dose adjustment; prasugrel requires only a single CYP step (compared to clopidogrel's two steps) and is not meaningfully affected by CYP2C19 intermediate metabolizer status.
Option D: Option D is incorrect: prasugrel dose reduction is weight-based (below 60 kg), not sex-based; female sex alone does not trigger a dose reduction.
Option E: Option E is incorrect: prasugrel active metabolite is not primarily renally eliminated, and renal impairment is not an indication for prasugrel dose reduction; the dose adjustment is weight-based per the TRITON-TIMI 38 subgroup data.
22. A 64-year-old man with a prior NSTEMI (non-ST-elevation myocardial infarction) underwent high-risk PCI (percutaneous coronary intervention) with drug-eluting stent placement and has now completed 3 months of uneventful DAPT (dual antiplatelet therapy) with ticagrelor 90 mg twice daily plus aspirin 81 mg. His cardiologist is considering a P2Y12 monotherapy de-escalation strategy — stopping aspirin while continuing ticagrelor — based on evidence from the TWILIGHT trial. Which of the following most accurately describes the TWILIGHT trial's primary finding regarding this de-escalation approach?
A) In TWILIGHT, ticagrelor monotherapy after 3 months of DAPT versus continued standard-dose clopidogrel alone reduced clinically relevant bleeding but was associated with a significantly higher rate of stent thrombosis (1.8% vs. 0.4%), indicating that the reduction in bleeding came at a meaningful ischemic cost that limits its application to low-risk patients.
B) In TWILIGHT, continued DAPT (ticagrelor plus aspirin for 12 months total) versus ticagrelor monotherapy after 3 months was superior in reducing the primary ischemic composite endpoint; the trial was stopped early when the DSMB (Data Safety Monitoring Board) determined the ischemic harm in the monotherapy arm was unacceptable.
C) In TWILIGHT, ticagrelor plus placebo (aspirin stopped at 3 months) versus ticagrelor plus aspirin continued in high-risk PCI patients reduced clinically relevant bleeding by 44% (4.0% vs. 7.1%) at 1 year without a statistically significant increase in the composite ischemic endpoint of death, MI, or stroke.
D) In TWILIGHT, aspirin monotherapy after stopping ticagrelor at 3 months was compared to continued DAPT; aspirin monotherapy significantly reduced major bleeding but also resulted in significantly higher 12-month MACE (major adverse cardiac events), limiting this strategy to patients at extremely high bleeding risk.
E) In TWILIGHT, de-escalation from ticagrelor plus aspirin to clopidogrel plus aspirin at 3 months was non-inferior to continued ticagrelor-based DAPT for the composite ischemic endpoint; the study established de-escalation to clopidogrel as the preferred maintenance strategy in high-risk PCI patients.
ANSWER: C
Rationale:
The TWILIGHT trial (n = 7,119) was a randomized, double-blind, placebo-controlled trial that enrolled high-risk PCI patients (based on clinical and angiographic features) who had completed 3 months of DAPT with ticagrelor plus aspirin without a major ischemic or bleeding event. Patients were then randomized to ticagrelor plus placebo (aspirin stopped) or ticagrelor plus aspirin continued for an additional 12 months. The primary endpoint — clinically relevant bleeding (BARC type 2, 3, or 5) — was significantly reduced by 44% in the ticagrelor monotherapy group (4.0% vs. 7.1%; hazard ratio 0.56). The key secondary endpoint — the composite of death, MI (myocardial infarction), or stroke — was not significantly different between arms (3.9% vs. 3.9%), confirming that stopping aspirin while continuing ticagrelor maintained ischemic protection. TWILIGHT established P2Y12 monotherapy (ticagrelor preferred based on this data) after a brief DAPT period as a viable de-escalation strategy in high-risk PCI patients seeking to reduce bleeding risk.
Option A: Option A is incorrect: ticagrelor monotherapy in TWILIGHT did not produce a significantly higher rate of stent thrombosis; stent thrombosis rates were similar between arms (approximately 0.4% in each), and there was no net ischemic harm.
Option B: Option B is incorrect: the TWILIGHT trial was not stopped early for ischemic harm; it completed enrollment and demonstrated that ticagrelor monotherapy did not increase ischemia while reducing bleeding.
Option D: Option D is incorrect: TWILIGHT compared ticagrelor plus placebo versus ticagrelor plus aspirin — it did not evaluate aspirin monotherapy after stopping ticagrelor; that strategy was not tested in TWILIGHT.
Option E: Option E is incorrect: TWILIGHT did not compare de-escalation to clopidogrel plus aspirin; it specifically tested aspirin discontinuation while maintaining ticagrelor; de-escalation to clopidogrel-based regimens was evaluated in separate trials such as TROPICAL-ACS.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.